Filtered By:
Therapy: Endocrine Therapy
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 2859 results found since Jan 2013.
Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer
CONCLUSION: Ultra-hypofractionated WBI + SIB in 5 fractions over one-week is feasible and well tolerated, although longer follow-up is necessary to confirm these results.PMID:37388711 | PMC:PMC10300060 | DOI:10.1016/j.ctro.2023.100651
Source: Clinical Breast Cancer - June 30, 2023 Category: Cancer & Oncology Authors: Angel Montero Raquel Ci érvide Carmen Ca ñadillas Beatriz Álvarez Mariola Garc ía-Aranda Rosa Alonso Mercedes L ópez Xin Chen-Zhao Leyre Alonso Jeannete Valero Emilio S ánchez Ovidio Hernando Paz Garc ía de Acilu Pedro Fernandez-Let ón Carmen Rubi Source Type: research
Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers
Cancer Res. 2023 Jun 29:CAN-23-0705. doi: 10.1158/0008-5472.CAN-23-0705. Online ahead of print.ABSTRACTCyclin-dependent-kinase-4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is standard of care for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC). However, resistance to CDK4/6is plus ET remains a clinical problem with limited therapeutic options following disease progression. Different CDK4/6is might have distinct mechanisms of resistance, and therefore using them sequentially or targeting their differentially altered pathways could delay disease progression. To understand pat...
Source: Cell Research - June 29, 2023 Category: Cytology Authors: Juliana Navarro-Yepes Nicole M Kettner Xiayu Rao Cassandra Santaella Bishop Tuyen N Bui Hannah F Wingate Akshara Singareeka Raghavendra Yan Wang Jing Wang Aysegul A Sahin Funda Meric-Bernstam Kelly K Hunt Senthil Damodaran Debu Tripathy Khandan Keyomarsi Source Type: research
Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic
CONCLUSION: OET adherence was significantly reduced during the COVID-19 pandemic in racial/ethnic minority patients with low SES. Patient-centered interventions are necessary to improve OET adherence in these patients.PMID:37380914 | DOI:10.1007/s11096-023-01609-6
Source: Clinical Genitourinary Cancer - June 28, 2023 Category: Cancer & Oncology Authors: Sama Rahimi Onyebuchi Ononogbu Anjana Mohan Daniel Moussa Susan Abughosh Meghana V Trivedi Source Type: research
Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
J Clin Oncol. 2023 Jun 26:JCO2301239. doi: 10.1200/JCO.23.01239. Online ahead of print.NO ABSTRACTPMID:37364222 | DOI:10.1200/JCO.23.01239
Source: Clinical Breast Cancer - June 26, 2023 Category: Cancer & Oncology Source Type: research
Pre-operative localisation of axillary lymph nodes using radiofrequency identification (RFID) tags: a feasibility assessment in 75 cases
CONCLUSIONS: The use of RFID tags for the preoperative localisation of axillary nodes is safe and feasible.PMID:37355355 | DOI:10.1016/j.crad.2023.05.017
Source: Clinical Genitourinary Cancer - June 24, 2023 Category: Cancer & Oncology Authors: S Lowes S El Tahir S Koo S Amonkar A Leaver R Milligan Source Type: research
Dual-targeted and dual-sensitive self-assembled protein nanocarrier delivering hVEGI-192 for triple-negative breast cancer
In this study, we successfully engineered a self-assembled protein nanocarrier TfRBP9-hVEGI-192-ELP fusion protein (TVEFP) to deliver the therapeutic protein, human vascular endothelial growth inhibitor (hVEGI-192). This was found to be effective in inhibiting tumor angiogenesis in vivo. The protein nanocarrier effectively inhibited the progression of TNBC in vivo and showed the behavior of self-assembly, thermoresponsiveness, enzyme stimulation-responsiveness, tumor-targeting, biocompatibility, and biodegradability. Near-infrared imaging studies showed that fluorescent dye-stained TVEFP effectively aggregated at the tumor...
Source: International Journal of Biological Macromolecules - June 23, 2023 Category: Biochemistry Authors: Meiling Zhou Yuming Yao Shuo Ma Mingyuan Zou Yaya Chen Shijie Cai Fengfeng Zhao Huina Wu Feng Xiao GuliNazhaer Abudushalamu Xiaobo Fan Guoqiu Wu Source Type: research
